CatalystMarker
← board

SMNRW

distress 7/10 · high distress / dilution risk
$0.090%today-4% from 52w high
semnurpharma.com5 employeesFounded 2013Palo Alto, CA
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+0%

Price & events

-4.3% over 6M
$0.02$0.06$0.09Jun 26Jul 26Jul 2637kdilution: 424B3 offering (2026-07-07)dilution: 424B3 offering (2026-07-01)financing: 8-K private_placement (2026-07-07)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+350.0%
1W
—
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
-4.3%
All

Overview

Market Cap
$20.72M
Volume
7.30K
52 Week Range
$0.02 – $0.09
Total Shares
230.21M
Float Shares
48.69M
RVOL
0.77x
Beta
0.15

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 230,209,142 · 6 offerings/1y · 3 PIPEs
  • 2026-07-078-Kprivate_placement
  • 2026-07-07424B3offering
  • 2026-07-01424B3offering
  • 2026-06-15424B3offering
  • 2026-06-15424B3offering
  • 2026-05-18EFFECTshelf_effective
  • 2025-12-29424B3offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.